ZGNX Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 jan 1970 @ 01:00):

Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States...

Stats
Dagens volum	11.25M
Gjennomsnittsvolum	3.10M
Markedsverdi	0.00
EPS	$-0.980 ( 2022-02-28 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.56
ATR14	$0.603 (2.26%)

Insider Trading

Date	Person	Action	Amount	type
2022-03-07	Breitmeyer James B	Sell	1 250	Common Stock
2022-03-07	Breitmeyer James B	Sell	9 375	Stock Option (Right to Buy)
2022-03-07	Breitmeyer James B	Sell	6 250	Stock Option (Right to Buy)
2022-03-07	Breitmeyer James B	Sell	9 000	Stock Option (Right to Buy)
2022-03-07	Breitmeyer James B	Sell	10 000	Stock Option (Right to Buy)

INSIDER POWER
0.00
Last 100 transactions
Buy: 446 833 \| Sell: 2 096 567

Volum Korrelasjon

Lang: 0.49 (neutral)

Kort: 0.91 (very strong)

Signal:(77.726) Expect same movement, but be aware

Zogenix Inc Korrelasjon

10 Mest positive korrelasjoner
BRACU	0.97
ATRS	0.969
ATCX	0.967
XLRN	0.957
CTSO	0.955
EYEN	0.952
ARAY	0.947
NVCN	0.946
ALGN	0.945
FOCS	0.945

10 Mest negative korrelasjoner
NAKD	-0.948
TRIT	-0.935
AHPI	-0.931
AMRB	-0.922
GRPH	-0.922
GRIN	-0.909
PROC	-0.907
CHKEL	-0.905
TUEM	-0.904
LAWS	-0.902

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Zogenix Inc Korrelasjon - Valuta/Råvare

-0.45
( neutral )

-0.59
( weak negative )

0.47
( neutral )

-0.65
( moderate negative )

-0.12
( neutral )

0.60
( weak )

Zogenix Inc Økonomi

Annual	2021
Omsetning:	$81.69M
Bruttogevinst:	$76.86M (94.08 %)
EPS:	$-4.24

FY	2021
Omsetning:	$81.69M
Bruttogevinst:	$76.86M (94.08 %)
EPS:	$-4.24

FY	2020
Omsetning:	$13.64M
Bruttogevinst:	$13.10M (96.03 %)
EPS:	$-3.90

FY	2019
Omsetning:	$3.65M
Bruttogevinst:	$3.65M (100.00 %)
EPS:	$-9.74

Financial Reports:

No articles found.

Zogenix Inc

Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.